Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Caribou is expected to release Q1 2026 results before the market opens on May 14, with analysts projecting ($0.33) EPS and $2.213M in revenue, and an earnings call scheduled for May 15 at 4:00 PM ET.
• In the prior quarter the company reported ($0.28) EPS and $3.94M in revenue (beating estimates), but remains deeply unprofitable—negative net margin of 1,327.4% and analysts forecast about -$1 EPS for the current and next fiscal year.
• The stock trades around $1.95 (market cap ~$192M) with a 52-week range of $0.73–$3.54; Wall Street ratings are mixed but average to a "Moderate Buy" with an average target of $8.00.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $2.2130 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.05. The company had revenue of $3.94 million during the quarter, compared to analysts' expectations of $1.96 million. Caribou Biosciences had a negative net margin of 1,327.40% and a negative return on equity of 78.40%. On average, analysts expect Caribou Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Caribou Biosciences Stock Performance

NASDAQ:CRBU opened at $1.95 on Thursday. The company has a fifty day moving average of $1.97 and a two-hundred day moving average of $1.88. The stock has a market capitalization of $192.43 million, a PE ratio of -1.23 and a beta of 2.27. Caribou Biosciences has a fifty-two week low of $0.73 and a fifty-two week high of $3.54.

Wall Street Analyst Weigh In

CRBU has been the subject of a number of research analyst reports. Truist Financial upgraded shares of Caribou Biosciences to a "strong-buy" rating in a research report on Wednesday, March 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Caribou Biosciences in a research report on Monday, April 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Caribou Biosciences in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $8.00.

Institutional Investors Weigh In On Caribou Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in Caribou Biosciences by 80.0% during the fourth quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company's stock worth $39,000 after buying an additional 10,824 shares during the period. Creative Planning purchased a new position in Caribou Biosciences during the second quarter worth about $25,000. Invesco Ltd. boosted its stake in Caribou Biosciences by 187.2% during the fourth quarter. Invesco Ltd. now owns 35,063 shares of the company's stock worth $56,000 after buying an additional 22,856 shares during the period. Hudson Bay Capital Management LP purchased a new position in Caribou Biosciences during the second quarter worth about $30,000. Finally, Credit Agricole S A purchased a new position in Caribou Biosciences during the third quarter worth about $68,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company's core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.